Article
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
Cancer - 15 Dec 2007
Gadgeel Shirish M, Ali Shadan, Philip Philip A, Ahmed Fakhara, Wozniak Antoinette, Sarkar Fazlul H
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC), particularly those with tumors that have EGFR-TK domain mutations. Moreover, the EGFR and cyclooxygenase (COX)-2 pathways are known to enhance the procarcinogenic effects of each other in different tumor types. Therefore, it was hypothesized...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.